Dividend growth stocks have generated higher annual total returns than all other stocks (i.e., non-dividend-paying stocks and other dividend-paying stocks) from 1973 to 2021. And this appears to still be the case in 2022.

As a case in point, pharma stock Eli Lilly (NYSE: LLY) has only fallen 1% year to date. This is significantly better than the S&P 500's 11% decline during that time. And better yet, I believe Eli Lilly can continue to outperform the S&P 500 going forward. Let's dive deeper into the stock's fundamentals and valuation to find out why.

Image source: Getty Images.

Continue reading

Source Fool.com